Novartis receives Japanese approval for Zolgensma in spinal muscular atrophy

This article was originally published here

A rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, SMA results in the rapid and irreversible loss of motor neurons, affecting muscle functions,

The post Novartis receives Japanese approval for Zolgensma in spinal muscular atrophy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply